Drug Type Biosimilar, Monoclonal antibody |
Synonyms HLX 03, HLX-03, 汉达远 |
Target |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (02 Dec 2020), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Pediatric Crohn's Disease | CN | 22 May 2024 | |
Plaque psoriasis | CN | 22 May 2024 | |
Polyarticular Juvenile Idiopathic Arthritis | CN | 22 May 2024 | |
Uveitis | CN | 12 Apr 2021 | |
Ankylosing Spondylitis | CN | 02 Dec 2020 | |
Psoriasis | CN | 02 Dec 2020 | |
Rheumatoid Arthritis | CN | 02 Dec 2020 |
Phase 3 | 262 | (HLX03 group) | sgtjumjang(ctboyphhnv) = iapyfifnnr avbexljqhu (sdvwotfpke ) | Positive | 23 Nov 2021 | ||
(adalimumab group) | sgtjumjang(ctboyphhnv) = gplzowicyu avbexljqhu (sdvwotfpke ) |